Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04515836 · ClinicalTrials.gov registry record · Phase 2
Olaparib in Patients With HRD Malignant Mesothelioma
A Phase 2 study of Mesothelioma and Homologous Recombination Deficiency, sponsored by University of Chicago.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 56
- Enrollment target
- 1
- Study location
NCT04515836: Recruiting Phase 2 study of Mesothelioma and Homologous Recombination Deficiency, sponsored by University of Chicago.
NCT04515836 is a Phase 2 study of Mesothelioma and Homologous Recombination Deficiency that is actively recruiting participants, run by University of Chicago. The registered enrollment target is 56 participants, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (72% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04515836, a Phase 2 study of Mesothelioma and Homologous Recombination Deficiency, is actively recruiting participants, sponsored by University of Chicago.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 56 participants
- Enrollment target
- 1
- Study location
Study Summary
In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
Primary Outcome
To determine the percentage of patients with mesothelioma tumors (containing certain gene/cell mutations) that shrink or stop growing as a response to olaparib.
Conditions Studied
Interventions
- DRUG Olaparib
Study Locations (1)
Illinois
- University of Chicago Medical Center - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 56 participants |
| Start Date | 2021-02-19 |
| Est. Completion | 2028-04-15 |
| Phase | Phase 2 |
What NCT04515836 shows while recruiting
NCT04515836 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 56 participants, a relatively small participant target, below the 197-participant average among 46 other Mesothelioma trials with a reported enrollment target (72% lower).
The record links to 2 conditions, with Mesothelioma appearing as the primary indexed condition, and to 1 intervention - of which Olaparib is the first listed.
NCT04515836 reports a single indexed study location in Illinois.
Frequently Asked Questions
What is clinical trial NCT04515836 about?
NCT04515836 is a clinical study titled "Olaparib in Patients With HRD Malignant Mesothelioma". In this study, researchers will give olaparib (a drug) to mesothelioma patients who have specific changes in their DNA (known as gene mutations). Researchers will give this drug to each patient on the study to find out if it will help the patient's tumor shrink or stop growing.
What is the current status of trial NCT04515836?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 56 participants. The study started on 2021-02-19. Estimated completion is 2028-04-15.
What conditions does trial NCT04515836 study?
This clinical trial studies the following conditions: Mesothelioma, Homologous Recombination Deficiency.
What interventions are being tested in trial NCT04515836?
The interventions under investigation include: Olaparib (DRUG).
Who is sponsoring clinical trial NCT04515836?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04515836 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mesothelioma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04515836's enrollment target sits among peer trials
56 32nd of 46 higher than 15 of 46 other Mesothelioma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mesothelioma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Sacituzumab Govitecan in People With Mesothelioma
RECRUITING · Phase 2
-
Adoptive Transfer of Tumor Infiltrating Lymphocytes for Advanced Solid Cancers
RECRUITING · Phase 2
-
MAGIC AKI: Magnesium for the Prevention of HIOC-Associated AKI
RECRUITING · Phase 2
-
18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection
RECRUITING · Phase 2
-
A Study of Additional Chemotherapy After Surgery for People With Malignant Peritoneal Mesothelioma
RECRUITING · Phase 2
-
Neoadjuvant Immune Checkpoint Blockade in Resectable Malignant Pleural Mesothelioma
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02287428 · 56 participants · Phase 1
Personalized NeoAntigen Cancer Vaccine w RT Plus Pembrolizumab for Patients With Newly Diagnosed GBM
- NCT02923011 · 56 participants · Phase 3
Comparative Effectiveness of MRgFUS Versus CTgRFA for Osteoid Osteomas
- NCT02935283 · 56 participants
Neuroimaging and Neuropsychological Outcomes in Urea Cycle Disorders
- NCT03375866 · 56 participants · NA
Effects of Mixed Nut Consumption on Satiety and Weight Management
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI